EndoGastric Solutions

OverviewSuggest Edit

EndoGastric Solutions is a medical technology company that develops incisionless transoral procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease and other GI disorders. It designs and manufactures EsophyX for use in endoluminal, transoral tissue approximation, thickness placation, and ligation in the GI tract. Its EsophyX is also indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. 

TypePrivate
Founded2002
HQRedmond, US
Websiteendogastricsolutions.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Sept 2020)71(+5%)
Cybersecurity ratingAMore

Key People/Management at EndoGastric Solutions

Skip Baldino

Skip Baldino

President and CEO, Director
Brent Ahrens

Brent Ahrens

Director
Michael Burke

Michael Burke

Chief Financial Officer
Darren Crow

Darren Crow

Vice President, R&D Operations
Michael Carusi

Michael Carusi

Director
Adrian Lobontiu

Adrian Lobontiu

Chief Medical Officer
Show more

EndoGastric Solutions Office Locations

EndoGastric Solutions has offices in Redmond and San Mateo
Redmond, US (HQ)
18109 NE 76th St #100
San Mateo, US
1900 O'Farrell St #325
Show all (2)

EndoGastric Solutions Financials and Metrics

Summary Metrics

Founding Date

2002

EndoGastric Solutions total Funding

$312.3 m

EndoGastric Solutions latest funding size

$14.50 m

Time since last funding

a year ago

EndoGastric Solutions investors

EndoGastric Solutions's latest funding round in May 2019 was reported to be $14.5 m. In total, EndoGastric Solutions has raised $312.3 m
Show all financial metrics

EndoGastric Solutions Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

EndoGastric Solutions Online and Social Media Presence

Embed Graph

EndoGastric Solutions News and Updates

United States Anti-Reflux Devices Markets Report, 2019-2025 Featuring Torax Medical, EndoGastric Solutions, Mederi Therapeutics & Medigus

DUBLIN, March 28, 2019 /PRNewswire/ -- The "Anti-Reflux Devices Market Report - United States - 2019-2025" report has been added to ResearchAndMarkets.com's offering. The value of the anti-reflux device market increased in 2018, and strong growth is expected to continue over the forecast...

EndoGastric Solutions Blogs

Interview: Dr. John Pandolfino discusses role of TIF procedure in GERD

A Precision Approach to Gastroesophageal Reflux Disease The Reason an Anatomical Fix is used to Control GERD Why Procedures (and Not Pills) Are Needed To Treat GERD TIF Procedure: A Nuanced Approach To Fundoplication TIF Procedure: A Strategic Move in the GERD Chess Game Why Repair Multiple Componen…

EndoGastric Solutions Announces Data Presented at ACG 2018 Provide Additional Validation of the Safety and Clinical Efficacy of TIF 2.0 Procedure for the Treatment of GERD

Amit Sohagia, MD received ACG’s Outstanding Poster Presenter Award for TIF 2.0 procedure poster REDMOND, Wash. – EndoGastric®Solutions today announced the presentation of three posters at the American College of Gastroenterology (ACG) 2018 Annual Scientific Meeting and Postgraduate Course, highlight…

EndoGastric Solutions Secures $30.5 Million In New Financing

Existing and New Investors Participated in Support of Rapid Commercialization Redmond, Washington. – EndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today that it has secured $30.5 million in new financing led by existin…

EndoGastric Solutions Announces New Data at Digestive Disease Week 2018 Supporting the Durability and Efficacy of TIF 2.0 Procedure for GERD Patients

TIF 2.0 procedure provides improved quality of life and elimination of daily PPI use for up to 10 years in patients with symptomatic GERD; TIF 2.0 procedure combined with laparoscopic hiatal hernia repair is a safe and effective option for patients with severe GERD and hiatal hernia REDMOND, Wash – …

EndoGastric Solutions Announces Publication of Meta-Analysis Further Validating TIF 2.0 procedure as an Appropriate Treatment Option for Refractory GERD Patients

TIF Procedure offers excellent short and long-term relief for the majority of chronic GERD patients. REDMOND, Wash – EndoGastric® Solutions today announced the publication of a meta-analysis supporting the clinical utility of Transoral Incisionless Fundoplication (TIF®) 2.0 in the treatment of refra…
Show more

EndoGastric Solutions Frequently Asked Questions

  • When was EndoGastric Solutions founded?

    EndoGastric Solutions was founded in 2002.

  • Who are EndoGastric Solutions key executives?

    EndoGastric Solutions's key executives are Skip Baldino, Brent Ahrens and Michael Burke.

  • How many employees does EndoGastric Solutions have?

    EndoGastric Solutions has 71 employees.

  • Who are EndoGastric Solutions competitors?

    Competitors of EndoGastric Solutions include Hound Labs, Bardy Diagnostics and Isomark.

  • Where is EndoGastric Solutions headquarters?

    EndoGastric Solutions headquarters is located at 18109 NE 76th St #100, Redmond.

  • Where are EndoGastric Solutions offices?

    EndoGastric Solutions has offices in Redmond and San Mateo.

  • How many offices does EndoGastric Solutions have?

    EndoGastric Solutions has 2 offices.